Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1
- 26 April 2012
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 444 (1), 79-88
- https://doi.org/10.1042/bj20111929
Abstract
SphK (sphingosine kinase) is the major source of the bioactive lipid and GPCR (G-protein-coupled receptor) agonist S1P (sphingosine 1-phosphate). S1P promotes cell growth, survival and migration, and is a key regulator of lymphocyte trafficking. Inhibition of S1P signalling has been proposed as a strategy for treatment of inflammatory diseases and cancer. In the present paper we describe the discovery and characterization of PF-543, a novel cell-permeant inhibitor of SphK1. PF-543 inhibits SphK1 with a Ki of 3.6 nM, is sphingosine-competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform. In 1483 head and neck carcinoma cells, which are characterized by high levels of SphK1 expression and an unusually high rate of S1P production, PF-543 decreased the level of endogenous S1P 10-fold with a proportional increase in the level of sphingosine. In contrast with past reports that show that the growth of many cancer cell lines is SphK1-dependent, specific inhibition of SphK1 had no effect on the proliferation and survival of 1483 cells, despite a dramatic change in the cellular S1P/sphingosine ratio. PF-543 was effective as a potent inhibitor of S1P formation in whole blood, indicating that the SphK1 isoform of sphingosine kinase is the major source of S1P in human blood. PF-543 is the most potent inhibitor of SphK1 described to date and it will be useful for dissecting specific roles of SphK1-driven S1P signalling.Keywords
This publication has 38 references indexed in Scilit:
- Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphateBiochemical Journal, 2011
- Development of Amidine-Based Sphingosine Kinase 1 Nanomolar Inhibitors and Reduction of Sphingosine 1-Phosphate in Human Leukemia CellsJournal of Medicinal Chemistry, 2011
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulationProceedings of the National Academy of Sciences of the United States of America, 2010
- Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-PhosphateScience, 2009
- The vascular S1P gradient—Cellular sources and biological significanceBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- “Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic TargetsPharmacological Reviews, 2008
- Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff diseaseHuman Molecular Genetics, 2008
- Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of Sphingosine KinaseDigestive Diseases and Sciences, 2007
- Antitumor Activity of Sphingosine Kinase InhibitorsThe Journal of pharmacology and experimental therapeutics, 2006
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974